Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting-Reference-Cited by-同舟云学术

Improved Glycemic Control and Reduction of Cardiometabolic Risk Factors in Subjects with Type 2 Diabetes and Metabolic Syndrome Treated with Exenatide in a Clinical Practice Setting

Published:2009-06 Issue:6 Volume:11 Page:353-359
ISSN:1520-9156
Container-title:Diabetes Technology & Therapeutics
language:en
Short-container-title:Diabetes Technology & Therapeutics

Author:

Bhushan Rajat¹,Elkind-Hirsch Karen E.¹,Bhushan Madhu¹,Butler William J.¹,Duncan Kelly¹,Marrioneaux Ory¹

Affiliation:

1. Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana.

Publisher

Mary Ann Liebert Inc

Subject

Medical Laboratory Technology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.liebertpub.com/doi/pdf/10.1089/dia.2008.0090

Reference37 articles.

1. Banting lecture 1988. Role of insulin resistance in human disease

2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

3. Definition of Metabolic Syndrome

4. The metabolic syndrome—a new worldwide definition

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial dysfunction in metabolic disorders;Mitochondrial Dysfunction and Nanotherapeutics;2021

2. Endothelial Dysfunction and Platelet Hyperaggregation in type 2 Diabetes Mellitus: The era of novel anti-diabetic agents;Current Medicinal Chemistry;2020-10-09

3. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors;Metabolism;2020-10

4. Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes;Journal of Clinical Medicine;2020-03-26

5. Future perspectives of the pharmacological management of diabetic dyslipidemia;Expert Review of Clinical Pharmacology;2019-01-22